Bumex for treatment of edema from heart, liver, and kidney diseases

Bumex is a potent loop diuretic tablet used to reduce excess fluid buildup (edema) caused by congestive heart failure, liver disease, or kidney disorders including nephrotic syndrome. Available in 0.5 mg, 1 mg, and 2 mg oral tablets, Bumex acts rapidly to increase urine output by blocking sodium and chloride reabsorption in the kidneys.

Bumex tablets are prescribed to treat edema associated with:

• Congestive heart failure
• Hepatic disease including cirrhosis with ascites
• Renal disease, including nephrotic syndrome

Bumex can be given orally, or by intramuscular or intravenous injection when gastrointestinal absorption is impaired or oral administration is not practical.

Bumetanide

Bumex works by inhibiting sodium and chloride reabsorption primarily in the ascending limb of the loop of Henle within the kidneys. This action increases the excretion of water, sodium, chloride, potassium, and chloride ions, producing a diuretic effect that helps reduce fluid retention. Bumex's onset of diuresis occurs within 30 to 60 minutes after oral administration, with peak effect in 1 to 2 hours, and lasts about 4 to 6 hours depending on the dose.

Bumex tablets come in 0.5 mg (light green), 1 mg (yellow), and 2 mg (peach) strengths for oral use.

Dose and dosing frequency must be carefully individualized to the patient’s needs to avoid excessive fluid and electrolyte loss.

If oral administration is not feasible, Bumex may be given intramuscularly or intravenously.

• Anuria (no urine production)
• Severe electrolyte depletion until corrected
• Hepatic coma
• Hypersensitivity to Bumex
• Discontinue therapy if oliguria or marked increase in blood urea nitrogen or creatinine occurs during treatment of progressive renal disease

• Profound diuresis risk: Excessive or too frequent dosing can cause significant water and electrolyte depletion, dehydration, low blood volume, circulatory collapse, and risk of thrombosis, especially in elderly patients.
• Hypokalemia: Bumex can cause potassium loss, which requires monitoring and supplementation, especially for patients on digitalis, with heart failure, liver cirrhosis, aldosterone excess, nephropathy causing potassium loss, or a history of ventricular arrhythmias.
• Hepatic encephalopathy: Rapid electrolyte changes in patients with hepatic cirrhosis and ascites may precipitate encephalopathy and coma; initial treatment should be in a hospital setting.
• Ototoxicity: Bumex has been shown to cause hearing toxicity in animal studies and may pose a risk especially with high intravenous doses or renal impairment. Caution is advised when used with aminoglycoside antibiotics.
• Hypersensitivity: Patients allergic to sulfonamides may react to Bumex.
• Thrombocytopenia: Rare reports of low platelet counts require regular monitoring during treatment.

• Common reactions include electrolyte imbalances such as hypokalemia, hypocalcemia, and hypomagnesemia.
• Potential reversible increases in blood urea nitrogen and creatinine, particularly with dehydration or renal insufficiency.
• Rare blood disorders such as thrombocytopenia.
• Possible ototoxicity, especially with high intravenous doses and impaired renal function.

• Aminoglycosides and other ototoxic drugs: Concurrent use may increase risk of hearing damage, especially with impaired renal function and parenteral Bumex.
• Nephrotoxic drugs: Concomitant use should be avoided due to potential kidney toxicity.
• Lithium: Bumex reduces lithium clearance, greatly increasing risk of lithium toxicity.
• Probenecid: Decreases Bumex efficacy by inhibiting its renal tubular secretion; concurrent use is contraindicated.
• Indomethacin: Inhibits Bumex’s diuretic effect; combined therapy not recommended.
• Antihypertensives: Bumex can potentiate antihypertensive effects, requiring dose reduction of those agents.
• Digoxin and warfarin: No significant interactions observed.

Pregnancy: Animal studies show Bumex is not teratogenic but may have slight embryocidal effects at doses many times higher than human therapeutic levels. There are no adequate human studies. Use only if benefits justify risks to the fetus.

Lactation: Unknown if excreted in human milk. Nursing is generally not recommended during therapy.